CLINICAL_TRIALS
trial_result
· 2021-12-09
Clinical Trial Update: Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping [Phase 2]
Summary
Phase 2 study of eteplirsen in young Duchenne Muscular Dystrophy patients amenable to exon 51 skipping has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: COMPLETED | Results posted: 2021-12-09